MHRA suspension of licences for Omniscan and Magnevist Feb 2018
December 19, 2017
The MHRA have published details of the suspension of licences Omniscan and Magnevist, taking effect from 1 February 2018.
Further restrictions have been applied to other linear Gadolinium-containing contrast agents.
This update is in response to a European-level scientific review of gadolinium retention in the brain and other tissues. Currently, there is no evidence of harm due to gadolinium retention in the brain, although the data are limited.
Full details can be found at the following link, which also links to the MHRA’s Central Alerting System message to healthcare professionals.